Learn about IGALMI, a sublingual film for acute agitation in schizophrenia or bipolar I or II disorder in adults. Please see ISI and full PI on this website.
IGALMI(dexmedetomidine) sublingual film is supplied as a blue rectangular sublingual film, containing on its surface two darker blue spots in dose strengths of 120 mcg and 180 mcg and is packaged as individual films in heat-sealed foil pouches in 10-count and 30-count films per carton. The ...
Dexmedetomidine sublingual film is intended for sublingual or buccal administration. Prepare and administer under supervision of a clinician.Commercially available films contain 120 or 180 mcg of dexmedetomidine; the 120 or 180 mcg films may be cut in half to obtain doses of 60 or 90 mcg, ...
Dexmedetomidine buccal/sublingual (buccal/sublingual): side effects, dosage, interactions, FAQs, reviews. Used for: agitation, sedation
Real-world Survey of Clinical Experience Using Dexmedetomidine Sublingual Film for Acute Agitation in Over 200 Adults With Schizophrenia or Bipolar DisorderMae KwongHooks, MichaelHokett, SonjaSenior Care Pharmacist
BXCL501 (sublingual film of dexmedetomidine) 基本信息 药品名称 BXCL501; Igalmi 单方药品 右美托咪定 药品类别 微创新; 化药; 小分子 靶点 α2-adrenergic receptor 作用机制 α2-adrenergic receptor激动剂 药品简介 -- 研发机构 BioXcel Therapeutics 最高研发阶段 全球: 批准上市 中国: 临床前 ...
sublingual film dexmedetomidine for agitation in patients with dementia. How applicable sublingual film dexmedetomidine results will be to clinical practice remains to be determined. In the current trial, study participants had bipolar disorder I or II and elevated PEC, but it is not clear whether ...
X. Dosing: Sublingual for Agitation (Schizophrenia, Bipolar Disorder) Unlikely to be effective as single agent in moderate to severe Agitation Consider as adjunct to other measures Mild to moderate Agitation Initial: 120 mcg sublingual or buccal Repeated: 60 mcg SL every 2 hours prn for up to...
Background and Objectives: Noradrenergic dysregulation is important in the pathophysiology of posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD); pharmacotherapies targeting adrenergic function have potential as treatment for comorbidity. Dexmedetomidine (sublingual film formulation...